Cancer clinical trials in the region Nouvelle-Aquitaine

454 currently recruiting clinical trials
Region Nouvelle-Aquitaine
Phase 3 Myelodysplastic Syndromes (MDS) and Myeloproliferative Neoplasms (MPN) #NCT07357727 #2025-523555-66-00
Required histologic types
Myeloproliferative neoplasms (MPN)
Required histologic sub types
Primary myelofibrosis Secondary myelofibrosis
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
Required DIPSS scores
Intermediate-1 Intermediate-2 High
Excluded previous treatments
Targeted therapy Allogeneic stem cell transplant
12 recruiting sites
Novartis Pharmaceuticals
Phase 3 Skin cancer #NCT06264180
Required histologic types
Melanoma
Required histologic sub types
Nodular melanoma Lentigo maligna melanoma Superficial spreading melanoma Acral lentiginous melanoma Achromic melanoma
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
BRAF
Required number of previous lines of therapy for current stage of disease
1 2
Required previous treatments at advanced or metastatic stage
Immunotherapy Targeted therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
7 recruiting sites
Replimune
Phase 3 Stomach and esophageal cancer #NCT06644781 #2023-509630-19-00
Required histologic types
Esophagus
Required histologic sub types
Squamous cell carcinoma
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
1
Required previous treatments at advanced or metastatic stage
Immunotherapy Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
18 recruiting sites
Daiichi Sankyo
Phase 3 Prostate cancer #NCT06136650 #2023-504957-11-00
Required histologic sub types
Adenocarcinoma
Required disease stage
Metastatic Castration-resistant
Required previous treatments at localized stage
Hormone therapy
Required previous treatments at advanced or metastatic stage
Hormone therapy
Excluded previous treatments at localized stage
Systemic Treatment-Naive Internal Vectorised Radiotherapy (IVR)
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive Internal Vectorised Radiotherapy (IVR)
10 recruiting sites
Merck Sharp & Dohme LLC
Phase 3 Breast cancer #NCT07492641 #2025-523960-19-00
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Positive
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded previous treatments at localized stage
Targeted therapy
Excluded previous treatments at advanced or metastatic stage
Targeted therapy
7 recruiting sites
BeOne Medecines
Phase 3 Breast cancer #NCT07492641 #2025-523960-19-00
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Positive
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
7 recruiting sites
BeOne Medecines
Phase 3 Colon cancer Rectal cancer #NCT06107920 #2024-516456-17-00
Required histologic sub types
Adenocarcinoma
Required disease stage
Localized
Required genetic anomalies
MSS/pMMR
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Surgery Chemotherapy Radiotherapy
28 recruiting sites
Hôpital universitaire de Rouen
Phase 3 Prostate cancer #NCT05939414 #2022-502956-29-00
Required disease stage
Biochemical recurrence Metastatic Hormone-sensitive
Required PSMA PET Scan statuses
PSMA PET Positive
Required number of previous lines of therapy for current stage of disease
None 1
Required previous treatments at localized stage
Surgery Radiotherapy
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded previous treatments at localized stage
Hormone therapy
6 recruiting sites
Novartis Pharmaceuticals
Phase 3 Sarcoma and GIST #NCT04307277 #2024-515384-62-00
Required histologic types
Soft tissue sarcoma
Required disease stage
Localized
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Surgery
Required sarcoma grades
Grade 1 Grade 2 Grade 3
20 recruiting sites
Institut Claudius Regaud
Phase 3 Lung cancer #NCT07218146 #2025-522818-23-00
Required histologic types
SCLC (Small Cell Lung Cancer)
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
1 2
Required previous treatments at localized stage
Chemotherapy Bispecific T-cell engager antibodies
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive Chemotherapy Bispecific T-cell engager antibodies
15 recruiting sites
Zai Lab (Shanghai) Co., Ltd